A cholesterol-lowering pill from Esperion Therapeutics Inc., ETC-1002 (bempedoic acid), significantly reduced LDL-cholesterol levels vs. placebo in a phase IIb study of patients with hypercholesterolemia on stable statin therapy, answering a key question for potential partners ahead of a planned phase III study later this year targeting statin-intolerant patients.